Case Report: Lenvatinib plus osimertinib treated a metastatic hilar cholangiocarcinoma patient harboring EGFR mutation

Peng Wang, Chentao Zou, Wendi Liu, Jiangli Xu, Hui Wang, Shisan Bao, Huabang Zhou

Open source

DOI: 10.3389/fimmu.2026.1949186
Published: 2026-10-22
Container: Frontiers in Immunology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1949186,
  title = {Case Report: Lenvatinib plus osimertinib treated a metastatic hilar cholangiocarcinoma patient harboring EGFR mutation},
  author = {Peng Wang and Chentao Zou and Wendi Liu and Jiangli Xu and Hui Wang and Shisan Bao and Huabang Zhou},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1949186},
  url = {https://doi.org/10.3389/fimmu.2026.1949186}
}

RIS

TY  - JOUR
TI  - Case Report: Lenvatinib plus osimertinib treated a metastatic hilar cholangiocarcinoma patient harboring EGFR mutation
AU  - Peng Wang
AU  - Chentao Zou
AU  - Wendi Liu
AU  - Jiangli Xu
AU  - Hui Wang
AU  - Shisan Bao
AU  - Huabang Zhou
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1949186
UR  - https://doi.org/10.3389/fimmu.2026.1949186
ER  -

APA

Wang, P., Zou, C., Liu, W., Xu, J., Wang, H., Bao, S., & Zhou, H. (2026). Case Report: Lenvatinib plus osimertinib treated a metastatic hilar cholangiocarcinoma patient harboring EGFR mutation. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1949186

Source records

crossref · retrieved 2026-11-08T09:08:16.531Z